Medical Device Network

Tandem showcases data from user survey of Tandem Mobi

Of the patients, 86% said they were satisfied or very satisfied with Mobi and agreed that it helps improve their quality of life.

Tandem Diabetes Care has shared positive new data from a user satisfaction and wearability survey, finding that 86% of participants were satisfied or very satisfied with its automated insulin delivery system Tandem Mobi.

The data was presented at the 84th Scientific Sessions of the American Diabetes Association (ADA) conference in Orlando, Florida, US, on 21–24 June.

Tandem Mobi – which launched in the US in February 2024 – is an automated insulin delivery system. The system leverages Control-IQ Technology, a prescription-only software that automates glucose levels using an algorithm that analyses continuous glucose monitor (CGM) readings and determines how much insulin to deliver.

The six-week survey involved early users who previously used multiple daily injections (MDI), other insulin pumps (tubed and tubeless) or previous tandem pumps. Of the prior MDI users, 84% said Mobi reduces the burden of managing diabetes and 82% labelled it easy to use. As well as this, 77% say Mobi helped them feel they have more freedom in their lives.

For prior pump users, 78% said the system reduces the diabetes management burden and 88% said it is easy to use, while 80% acknowledged it gives them more freedom in their lives.

According to San-Diego based Tandem, Mobi is currently the smallest durable automated insulin delivery system available in the US that is fully controllable from a mobile app. The Control-IQ hybrid closed-loop system is approved for use by individuals aged six and above with type 1 diabetes.

The system pairs with the DexCom G6 and G7 CGMs. Tandem also plans to integrate Mobi with the Abbott FreeStyle Libre 3 in the near future.

Tandem’s chief medical officer Jordan Pinsker said: “These real-world user insights provide evidence that we are furthering our mission to improve the lives of people with diabetes by demonstrating that Tandem Mobi not only meets, but exceeds user expectations.”

The US Food and Drug Administration (FDA) issued a Class I recall to Tandem last month, regarding version 2.7 of the Apple iOS t:connect mobile app that is used in conjunction with the t:slim X2 insulin pump, which uses Control-IQ technology. The app crash caused the pump’s battery to drain and shut down, causing 224 reported injuries and no deaths, as per the FDA.